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Poster Presentations: Sunday, July 14, 2019P492them. CERAD was the only test used in 1999, when 15.2% were
pre-menopausal and therefore was the only test used in this anal-
ysis. Mixed effect regression model was created to evaluate longi-
tudinal relationship between time since FMP and cognition. Results:
252 WHAP participants with complete data were included in this
analysis. Median (Q1-Q3) baseline time since FMP was 3.2(1-
5.5) years. Time since FMP was negatively associated with CE-
RAD delayed recall (b¼-0.14, 95%CI -0.16 to -0.12, p<0.001)
while controlling for education, APOE4, age at FMP and hormonal
treatment at the time of cognitive testing. Conclusions:The results
show that independent of potential confounders, prolonged time
since FMP leads to decrease in cognitive function over 15 years.
Further work needs to explore complex overlap between ageing,
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Background:Alzheimer’s disease and other dementias will increase
as the Mexican American (MA) population rapidly grows and ages.
There is an urgent need to better estimate the prevalence of cogni-
tive impairment or dementia (CID), cognitive decline trajectories,
and identify community resource needs for this population. The
Brain Attack Surveillance in Corpus Christi (BASIC)- Cognitive
project is a population-based study to detect CID, study informal
caregiving characteristics, and identify targets for improved care
and support among older MAs and non-Hispanic whites (NHW)
and their care partners in Nueces County, Texas; a community
with a large and primarily non-immigrant MA population.Methods:
Door-to-door surveillance is used to recruit community-dwelling
and nursing home residents aged 65 years or older and their
informal care partners. Households are identified from a two-stage
area probability sample of Nueces County housing units, with use
of Census data and ethnicity indicators to aim for an equal balance
of MA and NHW sampled households. The study targets n¼2100
cognitive screens (n¼ 1050MA, n¼ 1050 NHW; Figure 1). Those
with cognitive screens indicative of possible CID (Montreal Cogni-
tive Assessment, 25) complete neuropsychological assessment
(Harmonized Cognitive Assessment Protocol; HCAP). Informal
care partners complete comprehensive interview and needs assess-
ment. Study pairs repeat procedures at 2-year follow-up (Figure 2).
Asset and concept mapping are performed to identify available
community resources and to study care partners’ perceptions of
needs for individuals with CID. Results: During initial project
recruitment (5/1/18-1/15/19), 5437 households were approached,
and 852 age-eligible households were identified. 509 individuals
completed cognitive screening (298 MA, 190 NHW, 21 of other
race/ethnicity (ORE)), of which 360 (248 MA, 98 NHW, 14
ORE) were study-eligible and 277 named a care partner. 140 study
pairs (102 MA, 34 NHW, 4 ORE) have enrolled and completedHCAP and care partner interviews, with 80 refusals. The target
enrollment is 582 study pairs. Conclusions: Initial recruitment data
suggest robust participation within the MA community. The
BASIC-Cognitive study will provide critical information regarding
the prevalence of CID in MAs, the impact of caregiving, and allo-
cation of community resources to meet the needs of this growing
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Background: Pharmacological treatment with the current FDA-
approved AD medications for Alzheimer’s disease (AD) aim to
improve cognitive symptoms while several disease-modifying
agents are at various stages of clinical development. Understanding
disease progression in patients who use FDA-approved AD
